A Phase II Clinical Study of mFOLFOX6 /XELOX as Adjuvant Chemotherapy after Curative Resection of Stage III Colon Cancer: The FACOS Study

Keiichiro Ishibashi; Kensuke Kumamoto; Keiji Koda; Hiroyuki Kato; Genichi Nishimura; Kazuhiko Yoshimatsu; Hajime Yokomizo; Shinji Ooki; Soichi Tanaka; Michio Asano; Masaru Yokoyama; Tomoyuki Kawada; Hideyuki Ishida

doi:10.4993/acrt.24.17

Keiichiro Ishibashi, Kensuke Kumamoto, Keiji Koda, Hiroyuki Kato, Genichi Nishimura, Kazuhiko Yoshimatsu, Hajime Yokomizo, Shinji Ooki, Soichi Tanaka, Michio Asano, Masaru Yokoyama, Tomoyuki Kawada, Hideyuki Ishida

Author information

Keiichiro Ishibashi
Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University
Kensuke Kumamoto
Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University
Keiji Koda
Department of Surgery, Teikyo University Chiba Medical Center
Hiroyuki Kato
Department of Surgery, Sakura Medical Center, School of Medicine, Faculty of Medicine, Toho University
Genichi Nishimura
Department of Surgery, Japanese Red Cross Kanazawa Hospital
Kazuhiko Yoshimatsu
Department of Surgery, Tokyo Women's Medical University, Medical Center East
Hajime Yokomizo
Department of Surgery, Tokyo Women's Medical University, Medical Center East
Shinji Ooki
Department of Organ Regulatory Surgery, Fukushima Medical University
Soichi Tanaka
Department of Surgery, Matsuda Hospital
Michio Asano
Department of Surgery, Matsuda Hospital
Masaru Yokoyama
Department of Surgery, Higashimatsuyama Medical Association Hospital
Tomoyuki Kawada
Department of Hygiene and Public Health, Nippon Medical School
Hideyuki Ishida
Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University

Keywords: colon cancer, adjuvant chemotherapy, oxaliplatin

JOURNAL FREE ACCESS

2016 Volume 24 Issue 1 Pages 17-22

DOI https://doi.org/10.4993/acrt.24.17

J-STAGE : acrt 24 1 pp.41-41

Details

Abstract

This clinical study is being conducted to verify the efficacy and safety of oxaliplatin combined with a fluoropyrimidine derivative as adjuvant chemotherapy for patients with stage III colon cancer, since few clinical data are available for Japanese patients. The mFOLFOX6 and XELOX regimens are being investigated. The primary endpoint is 3-year disease-free survival, while the secondary endpoints are safety, the completion rate of study therapy, 2-year disease-free survival, and overall survival. It is planned to enroll 130 patients.

Corresponding author

Register with J-STAGE for free!